Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

DECLARE-TIMI 58: Participants’ baseline characteristics

(2018) Itamar Raz et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis

(2018) Samuel Seidu et al.   Primary Care Diabetes

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 Inhibitors and the Diabetic Kidney

(2016) Paola Fioretto et al.   DIABETES CARE

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

(2016) Paola Fioretto et al.   DIABETOLOGIA

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study

(2016) Michael A Weber et al.   Lancet Diabetes & Endocrinology

Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy

(2015) Marko Škrtić et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2015) Silvio E. Inzucchi et al.   DIABETOLOGIA

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

(2014) J. Dziuba et al.   DIABETES OBESITY & METABOLISM

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

(2014) Agata Ptaszynska et al.   DRUG SAFETY

Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes

(2014) Marianna Maranghi et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Effects of Dapagliflozin on Cardiovascular Risk Factors

(2013) Agata Ptaszynska et al.   POSTGRADUATE MEDICINE

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

(2012)   AMERICAN JOURNAL OF KIDNEY DISEASES

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Heart Rate Variability Predicts ESRD and CKD-Related Hospitalization

(2010) D. J. Brotman et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?

(2010) G. Schernthaner et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

(2009) J. P.H. Wilding et al.   DIABETES CARE

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE